The FDA recently approved a ‘two-fer’…. yep, TWO identical biosimilars with the approval of Jubbonti (denosumab-bbdz) and Wyost (denosumab-bbdz) from Sandoz, Inc. They are the same
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases
The FDA recently approved yet another – first in class -cellular therapy, Amtagvi (lifileucel) from Iovance Biotherapeutics Inc., indicated for the treatment of adult patients
It is not often that I see a report of an event that is so extraordinary that it is jaw dropping. A report that BioPlus Specialty
……..catching up on FDA approvals The FDA recently approved a new form of Eohilia (budesonide oral suspension) from Takeda , the first and only FDA-approved
……..catching up on FDA Approvals The FDA recently approved a new infused therapy, Avzivi (bevacizumab-tnjn) from Bio-Thera Solutions, as a biosimilar to AVASTIN (bevacizumab). It did not receive
The National Association of Specialty Pharmacy (NASP) recently released the results of a patient satisfaction survey of specialty pharmacies. The results are worth evaluating…… closely. Ultimately, satisfaction will
…… catching up o FDA approvals The FDA has approved a new specialty topical gel, Filsuvez (birch triterpenes) from Chiesi Farmaceutici S.p.A. Parma, indicated for
We’ve often written about the battle being fought around site-of-care. As we’ve suggested previously, it comes down to one word….. MONEY. Payers have been turning up
……………catching up on FDA approvals The FDA approved a new ORAL therapy, Fabhalta (iptacopan) from Novartis, the first oral monotherapy for the treatment of adults
